TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± Trastuzumab

Stefan Glück, Jeffrey S. Ross, Melanie Royce, Edward F. McKenna, Charles M. Perou, Eli Avisar, Lin Wu

Research output: Contribution to journalArticlepeer-review

139 Scopus citations

Fingerprint Dive into the research topics of 'TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± Trastuzumab'. Together they form a unique fingerprint.

Medicine & Life Sciences